Therapy Areas: Autoimmune
US FDA has Granted Priority Review of the Teprotumumab Biologics License Application for the Treatment of Active Thyroid Eye Disease
Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
6 September 2019 - - US-based biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has received final topline results from its recently completed dose-ranging Phase 2 trial eval...
Genor Biopharma Named Jack Hu as Chief Financial Officer and Chief Strategy Officer
6 September 2019 - - Chinese biopharmaceutical company Genor Biopharma has named Jack Hu as Chief Financial Officer and Chief Strategy Officer, the company said.
Before joining Genor, Dr. Hu ser...
Calliditas receives the FDA positive feedback for ongoing NefIgArd Pivotal Phase 3 Study in kidney disease
4 September 2019 - Pharmaceutical company Calliditas Therapeutics AB on Tuesday provided an update of the ongoing pivotal Phase 3 NefIgArd study with its leading drug candidate Nefecon for the chronic...
HiFiBiO Therapeutics Closes USD 67m Series C Financing
30 August 2019 - - US-based biotherapeutics developer HiFiBiO Therapeutics has closed a USD 67m Series C financing round. The funding was led by new investor IDG Capital, the company said.
...
HiFiBiO Therapeutics announces completion of USD67m Series C financing round
30 August 2019 - HiFiBiO Therapeutics, a US biotherapeutics company, has completed a USD67m Series C financing round, it was reported yesterday.The funding was headed by new investor, IDG Capital. The...